RESUMO
Azithromycin is an antibiotic used to treat syphilis, especially in the context of penicillin allergy. Although resistance to azithromycin has been widely reported to be associated with one- and/or two-point mutations on the 23S rRNA gene, it has yet to be described in Indonesia. Specimens were collected from 220 patients diagnosed with secondary syphilis. A multiplex nested polymerase chain reaction (PCR) testing system using the 23S rRNA target gene of Treponema pallidum was designed using three primer pairs. The first step involved the use of PCR primer pairs to detect T. pallidum. In the second step, two PCR primer pairs were constructed to identify azithromycin-resistant T. pallidum based on A2058G and A2059G point mutations. T. pallidum detected in samples from Jakarta or Bandung were not resistant to azithromycin. However, azithromycin-resistant T. pallidum were found in samples from Makassar, Medan, and Bali. Specimens from heterosexual males and patients with HIV accounted for the majority of azithromycin resistance noted in the study. This study demonstrated that the azithromycin-resistant T. pallidum detected in Indonesia appear to be a novel variant of resistance, containing both the A2058G and A2059G mutations found in Medan and Makassar.
Assuntos
Sífilis , Treponema pallidum , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Azitromicina/farmacologia , Farmacorresistência Bacteriana/genética , Genes de RNAr , Humanos , Indonésia , Macrolídeos , Masculino , Reação em Cadeia da Polimerase Multiplex , RNA Ribossômico 23S/genética , Treponema pallidum/genéticaRESUMO
<b>Background and Objective:</b> Detection of methicillin-resistant<i> S. aureus</i> have become a challenge in the presence of oxacillin-susceptible and <i>mecA</i>-positive <i>S. aureus </i>(OS-MRSA), concerning the misidentification events and therapeutic implications. This study aims to identify the OS-MRSA in clinical isolates of Post-viral acute rhinosinusitis, which, hopefully, can interfere with the therapeutic strategy. <b>Materials and Methods:</b> There were 60 patients diagnosed with Post-viral acute rhinosinusitis, recruited from an Ear, Nose and Throat (ENT) outpatient clinic. <i>Staphylococcus aureus</i> isolates were identified from the culture and were then tested for antibiotics susceptibility using a Kirby-Bauer disc diffusion test. The <i>mecA</i>, <i>mecC</i> and <i>blaZ</i> genes were determined using the Polymerase Chain Reaction (PCR) method. <b>Results:</b> <i>Staphylococcus aureus </i>was identified in 20 of the 60 samples from the patients (33.3%; 95% CI: 21.0-45.6). Of the 20 isolates, 19 isolates (95%) had a positive <i>mecA</i> gene, 19 (95%) had a positive <i>mecC</i> gene and 20 (100.0%) had a positive <i>blaZ </i>gene. The majority of the <i>mecA</i>-positive <i>S. aureus</i> showed an oxacillin-susceptible (85%) and 3 isolates (15.0%) were oxacillin-resistant toward the <i>S. aureus</i>. <b>Conclusion:</b> There was a high proportion of Oxacillin/cefoxitin-Susceptible <i>mecA</i>-positive <i>S. aureus</i> in the study population that indicate phenotypic susceptibility to antibiotics does not always indicate the absence of genes that carry resistant traits, thus allowing misidentification if the only phenotypic examination is carried out.
Assuntos
Antibacterianos/uso terapêutico , Proteínas de Bactérias/genética , Staphylococcus aureus Resistente à Meticilina/genética , Oxacilina/uso terapêutico , Proteínas de Ligação às Penicilinas/genética , Rinite/microbiologia , Sinusite/microbiologia , Infecções Estafilocócicas/microbiologia , Viroses/complicações , Testes de Sensibilidade a Antimicrobianos por Disco-Difusão , Farmacorresistência Bacteriana , Humanos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Rinite/diagnóstico , Rinite/tratamento farmacológico , Sinusite/diagnóstico , Sinusite/tratamento farmacológico , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológicoRESUMO
BACKGROUND: The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID-19 vaccines has moved quickly. In this study, we assessed the efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine and its lot-to-lot consistency. A total of 1620 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine or placebo on a day 0 and 14 schedule. This article was based on an interim report completed within 3 months following the last dose of study vaccine. The interim analysis includes safety and immunogenicity data for 540 participants in the immunogenicity subset and an efficacy analysis of the 1620 subjects. For the safety evaluation, solicited and unsolicited adverse events were collected after the first and second vaccination within 14 and 28 days, respectively. Blood samples were collected for an antibody assay before and 14 days following the second dose. RESULTS: Most of the adverse reactions were in the solicited category and were mild in severity. Pain at the injection site was the most frequently reported symptom. Antibody IgG titer determined by enzyme-linked immunosorbent assay was 97.48% for the seroconversion rate. Using a neutralization assay, the seroconversion rate was 87.15%. The efficacy in preventing symptomatic confirmed cases of COVID-19 occurring at least 14 days after the second dose of vaccine using an incidence rate was 65.30%. CONCLUSIONS: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles.
Assuntos
Vacinas contra COVID-19 , COVID-19 , Adulto , Anticorpos Neutralizantes , Anticorpos Antivirais , Método Duplo-Cego , Humanos , Imunogenicidade da Vacina , Indonésia/epidemiologia , SARS-CoV-2 , Vacinas de Produtos Inativados/efeitos adversosRESUMO
BACKGROUND: Human papillomavirus (HPV)-45 genotype circulates in high percentage in Bandung area - Indonesia, after HPV-16 and HPV-18. The aim of this study was to analyse variations of major capsid (L1) HPV-45 and its phylogeny. Furthermore in silico protein structure and epitope prediction was explored. METHODS: L1 gene of HPV-45 was amplified, sequenced and aligned. Phylogenetic tree had been built and compared with a complete L1 HPV-45 sequence. Structure and epitope prediction of L1 protein were then developed in silico. RESULTS: Of 5 L1 HPV-45 sequences collected, we have detected one variant of sub lineage A2 which was considered as a new variant, and two variants of B2. Superimposition of structure of these two variants with reference showed very similar structure. Furthermore, seven amino acid substitutions were found within these L1 variants of which two substitutions might change the polarity of corresponding amino acid I329T and S383G. The S383G occurred in surface loop (HI-Loop) of new L1 HPV-45 variant. CONCLUSION: Similar structure of Indonesian variants indicates that amino acids variations do not affect the L1 structure. However, one substitution with altered amino acid polarity found within the area of surface loop suggests a potential impact in antibody recognition and neutralization.
Assuntos
Alphapapillomavirus/genética , Proteínas do Capsídeo/química , Proteínas do Capsídeo/genética , Proteínas Oncogênicas Virais/química , Proteínas Oncogênicas Virais/genética , Infecções por Papillomavirus/complicações , Polimorfismo Genético , Neoplasias do Colo do Útero/epidemiologia , Alphapapillomavirus/isolamento & purificação , Sequência de Aminoácidos , Simulação por Computador , Feminino , Humanos , Indonésia/epidemiologia , Infecções por Papillomavirus/genética , Infecções por Papillomavirus/virologia , Filogenia , Prognóstico , Conformação Proteica , Homologia de Sequência , Neoplasias do Colo do Útero/genética , Neoplasias do Colo do Útero/virologiaRESUMO
BACKGROUND: Despite the rapid spread of antibiotic resistance in gonococci all over Southeast Asia, there is only limited surveillance for antibiotic susceptibility in Indonesia. GOAL: This study was undertaken to determine the frequency and diversity of antimicrobial resistance in gonococcal isolates from cohorts of female commercial sex workers in Bandung and Jakarta, Indonesia, and to characterize the Tet M plasmid among the tetracycline-resistant strains N gonorrhoeae. STUDY DESIGN: The antimicrobial susceptibility of 267 strains (85 strains from Bandung and 182 from Jakarta) to penicillin, spectinomycin, tetracycline, ciprofloxacin, cefotaxime, thiamphenicol, kanamycin, azithromycin, and trimethoprim-sulfamethoxazole (TMP-SMZ) was determined by agar dilution. Typing of the Tet M plasmid in tetracycline-resistant isolates was performed by PCR. RESULTS: Prevalence of penicillin and tetracycline resistance was extremely high: 60.0% of the isolates from Bandung and 70.9% of the isolates from Jakarta were resistant to penicillin. Of these, 60.0% and 62.1%, respectively, were penicillinase-producing N gonorrhoeae (PPNG). All the isolates from Bandung and 98.4% from Jakarta were resistant to tetracycline. All tetracycline-resistant isolates from Bandung and 97.8% from Jakarta carried a PCR fragment characteristic of the "Dutch" type Tet M plasmid. One isolate from Jakarta showed chromosomal resistance to tetracycline (0.6%). Chromosomal resistance to thiamphenicol (MIC, >/=2.0 microg/ml) was significantly higher in Jakarta than in Bandung (P < 0.05). All gonococcal isolates were susceptible to kanamycin, spectinomycin, cefotaxime, ciprofloxacin, and azithromycin. CONCLUSION: Spectinomycin, fluoroquinolones, and azithromycin are still useful primary drugs for treatment of gonococcal infections in Indonesia. Continued surveillance of antimicrobial susceptibility should be part of gonorrhea control in Indonesia.